Cue Biopharma, Inc. (CUE)
Largest Insider Buys in Sector
CUE Stock Price History Chart
CUE Stock Performance
About Cue Biopharma, Inc.
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate is CUE-101, a fusion protein biologic that is in Phase 1b clinical trial designed to target and activate antigen-specific T cells for human papilloma virus-driven cancers. The company offers CUE-102, a fusion protein biologic to target and activate antigen-specific T cells to fight cancers; CUE-103 a CUE-100 series Immuno-STAT targeting the KRAS G12V mutation, including colorectal carcinoma, lung cancer, and pancreatic cancer; CUE-200 that focuses on cell surface receptors, including CD80 and/or 4-1BBL to address T cell exhaustion associated with chronic infections; and CUE-300 and CUE-400 framework to target various autoimmune diseases. Cue Biopharma, Inc. has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for the development of Immuno-STATs focused on the field of oncology; and Albert Einstein College of Medicine. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Insider Activity of Cue Biopharma, Inc.
Over the last 12 months, insiders at Cue Biopharma, Inc. have bought $19,620 and sold $0 worth of Cue Biopharma, Inc. stock.
On average, over the past 5 years, insiders at Cue Biopharma, Inc. have bought $1.2M and sold $1.32M worth of stock each year.
Highest buying activity among insiders over the last 12 months: PASSERI DANIEL R (CHIEF EXECUTIVE OFFICER) — $17,160. Suri Anish (PRESIDENT AND CSO) — $11,040.
The last purchase of 4,000 shares for transaction amount of $11,040 was made by Suri Anish (PRESIDENT AND CSO) on 2023‑08‑25.
List of Insider Buy and Sell Transactions, Cue Biopharma, Inc.
| 2023-08-25 | Suri Anish | PRESIDENT AND CSO | 4,000 0.0088% | $2.76 | $11,040 | -23.84% | ||
| 2023-08-14 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 3,000 0.0065% | $2.86 | $8,580 | -29.32% | ||
| 2023-03-23 | Sale | Kiener Peter A | director | 9,325 0.0208% | $3.28 | $30,586 | -14.55% | |
| 2022-05-27 | Morich Frank | 28,000 0.0769% | $3.75 | $105,000 | -19.17% | |||
| 2022-05-23 | Fletcher Aaron G.L. | 55,000 0.1455% | $3.34 | $183,700 | -12.61% | |||
| 2022-03-31 | Fletcher Aaron G.L. | 735,000 2.0277% | $4.76 | $3.5M | -36.07% | |||
| 2021-11-16 | Sale | Kiener Peter A | director | 1,361 0.0046% | $18.02 | $24,525 | -77.86% | |
| 2021-11-15 | Sale | Suri Anish | President and CSO | 8,000 0.0257% | $18.05 | $144,400 | -78.74% | |
| 2021-11-15 | Sale | Kiener Peter A | director | 18,815 0.0599% | $17.92 | $337,165 | -78.74% | |
| 2021-11-11 | Sale | Suri Anish | President and CSO | 20,000 0.0634% | $15.07 | $301,354 | -74.37% | |
| 2021-10-01 | Sale | Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | 1,251 0.0039% | $14.21 | $17,783 | -66.60% | |
| 2021-09-24 | PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 3,400 0.011% | $14.72 | $50,051 | -65.45% | ||
| 2021-09-23 | Sale | Suri Anish | PRESIDENT AND CSO | 20,000 0.0648% | $15.23 | $304,646 | -66.40% | |
| 2021-03-16 | Sale | Pienta Kenneth | Chief Medical Officer | 439 0.0015% | $15.09 | $6,626 | -19.03% | |
| 2021-03-15 | Sale | Pienta Kenneth | Chief Medical Officer | 13,000 0.0427% | $15.10 | $196,269 | -20.52% | |
| 2021-02-17 | Sale | Pienta Kenneth | Chief Medical Officer | 4,274 0.0142% | $15.05 | $64,345 | -17.94% | |
| 2021-02-16 | Sale | Pienta Kenneth | Chief Medical Officer | 16,000 0.0525% | $15.15 | $242,422 | -19.24% | |
| 2021-01-20 | Sale | Pienta Kenneth | Chief Medical Officer | 2,720 0.0093% | $15.07 | $40,980 | -13.79% | |
| 2021-01-20 | Pienta Kenneth | Chief Medical Officer | 5,440 0.0187% | $15.07 | $81,959 | -13.79% | ||
| 2020-11-24 | Fletcher Aaron G.L. | director | 13,096 0.0466% | $12.64 | $165,552 | +4.77% |
Insider Historical Profitability
| Suri Anish | PRESIDENT AND CSO | 135638 0.3006% | $1.38 | 2 | 6 | +73.75% |
| PASSERI DANIEL R | CHIEF EXECUTIVE OFFICER | 134578 0.2982% | $1.38 | 6 | 0 | +4.56% |
| Fletcher Aaron G.L. | 940000 2.0832% | $1.38 | 4 | 0 | <0.0001% | |
| Gray Cameron | director | 677500 1.5014% | $1.38 | 2 | 0 | <0.0001% |
| DIGIANDOMENICO ANTHONY | director | 57000 0.1263% | $1.38 | 5 | 0 | +68.36% |
| Morich Frank | 28000 0.0621% | $1.38 | 1 | 0 | <0.0001% | |
| Sandercock Colin | SVP, General Counsel and Sec | 17125 0.038% | $1.38 | 3 | 3 | +52.57% |
| Millar Kerri-Ann | CHIEF FINANCIAL OFFICER | 10472 0.0232% | $1.38 | 1 | 1 | <0.0001% |
| Pienta Kenneth | Chief Medical Officer | 2000 0.0044% | $1.38 | 2 | 5 | <0.0001% |
| Kiener Peter A | director | 357 0.0008% | $1.38 | 0 | 3 | |
| MARLETT CHRISTOPHER A | director | 0 0% | $1.38 | 9 | 6 | +65.21% |
Institutional Investor Ownership
| Bleichroeder Lp | $5.21M | 5.66 | 2.76M | +56.98% | +$1.89M | 1.38 | |
| Slate Path Capital LP | $4.54M | 4.94 | 2.4M | 0% | +$0 | 0.09 | |
| The Vanguard Group | $4.32M | 4.69 | 2.28M | +7.05% | +$284,363.72 | <0.0001 | |
| BlackRock | $4.24M | 4.61 | 2.24M | -4.05% | -$178,911.15 | <0.0001 | |
| Geode Capital Management | $1.59M | 1.72 | 838,531 | +3.1% | +$47,721.55 | <0.0001 | |
| State Street | $1.44M | 1.56 | 759,795 | +11.13% | +$143,829.05 | <0.0001 | |
| Robertson Stephens Wealth Management Llc | $904,365.00 | 0.98 | 478,500 | 0% | +$0 | 0.01 | |
| Dimensional Fund Advisors | $815,172.00 | 0.89 | 431,308 | -5.83% | -$50,419.52 | <0.0001 | |
| Northern Trust | $690,195.00 | 0.75 | 365,182 | -4.24% | -$30,589.69 | <0.0001 | |
| Millennium Management LLC | $684,350.00 | 0.74 | 362,090 | +31.36% | +$163,381.03 | <0.0001 | |
| Monaco Asset Management Sam | $632,662.00 | 0.69 | 334,742 | -2.19% | -$14,174.99 | 0.29 | |
| Renaissance Technologies | $518,000.00 | 0.56 | 274,033 | +214.26% | +$353,167.30 | <0.01 | |
| Advisory Research | $486,155.00 | 0.53 | 257,225 | 0% | +$0 | 0.1 | |
| Sigma Planning Corp | $483,849.00 | 0.53 | 256,005 | +135.14% | +$278,075.44 | 0.02 | |
| Bank of America | $460,434.00 | 0.5 | 243,616 | -8.49% | -$42,734.77 | <0.0001 | |
| Gsa Capital Partners Llp | $395,000.00 | 0.43 | 209,100 | +1,398.71% | +$368,644.00 | 0.03 | |
| Stifel | $364,001.00 | 0.4 | 192,592 | -0.71% | -$2,613.89 | <0.0001 | |
| Morgan Stanley | $283,266.00 | 0.31 | 149,876 | -9% | -$28,028.74 | <0.0001 | |
| Nuveen | $276,556.00 | 0.3 | 146,326 | -23.6% | -$85,446.86 | <0.0001 | |
| Citadel Advisors LLC | $276,386.00 | 0.3 | 146,236 | +187.76% | +$180,339.99 | <0.0001 | |
| Squarepoint Ops LLC | $219,527.00 | 0.24 | 116,152 | +166.33% | +$137,100.42 | <0.01 | |
| Good Life Advisors LLC | $189,000.00 | 0.21 | 100,000 | 0% | +$0 | 0.02 | |
| UBS | $175,707.00 | 0.19 | 92,967 | -6.34% | -$11,895.62 | <0.0001 | |
| BNY Mellon | $174,270.00 | 0.19 | 92,207 | -15.68% | -$32,405.71 | <0.0001 | |
| Charles Schwab | $172,994.00 | 0.19 | 91,531 | -13.4% | -$26,762.46 | <0.0001 | |
| Hightower Advisors | $147,000.00 | 0.16 | 77,500 | -0.78% | -$1,157.03 | <0.0001 | |
| Cornercap Investment Counsel Inc | $109,408.00 | 0.12 | 57,888 | 0% | +$0 | 0.02 | |
| Goldman Sachs | $86,255.00 | 0.09 | 45,638 | -21.75% | -$23,976.31 | <0.0001 | |
| Wedmont Private Capital | $76,000.00 | 0.08 | 40,000 | New | +$76,000.00 | 0.01 | |
| Susquehanna International Group | $63,608.00 | 0.07 | 33,655 | +142.3% | +$37,355.88 | <0.0001 | |
| bakerave | $61,194.00 | 0.07 | 32,378 | 0% | +$0 | <0.0001 | |
| RhumbLine Advisers | $61,601.00 | 0.07 | 32,597 | +2.67% | +$1,600.64 | <0.0001 | |
| Barclays | $59,000.00 | 0.07 | 31,404 | -43.45% | -$45,324.64 | <0.0001 | |
| Wells Fargo | $58,379.00 | 0.06 | 30,888 | +4.98% | +$2,770.77 | <0.0001 | |
| Deutsche Bank | $56,324.00 | 0.06 | 29,801 | 0% | +$0 | <0.0001 | |
| Occudo Quantitative Strategies Lp | $54,954.00 | 0.06 | 29,076 | -13.05% | -$8,246.12 | 0.01 | |
| Nantahala Capital Management Llc | $50,448.00 | 0.06 | 26,692 | 0% | +$0 | 0.01 | |
| Navalign Wealth Partners | $47,250.00 | 0.05 | 25,000 | 0% | +$0 | 0.02 | |
| Cambridge Investment Research Advisors Inc | $42,000.00 | 0.05 | 22,200 | 0% | +$0 | <0.0001 | |
| Two Sigma | $37,751.00 | 0.04 | 19,974 | New | +$37,751.00 | <0.0001 | |
| Carlson Capital, L.P. | $37,800.00 | 0.04 | 20,000 | -83.33% | -$189,000.00 | <0.01 | |
| American International Group | $33,519.00 | 0.04 | 17,735 | -0.85% | -$289.17 | <0.0001 | |
| JPMorgan Chase | $29,156.00 | 0.03 | 15,426 | -31.26% | -$13,258.74 | <0.0001 | |
| Invesco | $28,741.00 | 0.03 | 15,207 | -0.88% | -$255.15 | <0.0001 | |
| Voya Investment Management LLC | $25,400.00 | 0.03 | 13,439 | -7.69% | -$2,114.93 | <0.0001 | |
| LINSCO PRIVATE LEDGER CORP | $24,428.00 | 0.03 | 12,925 | 0% | +$0 | <0.0001 | |
| SeaCrest Investment Management, LLC | $24,570.00 | 0.03 | 13,000 | -7.14% | -$1,890.00 | <0.01 | |
| Acadian Asset Management | $23,000.00 | 0.03 | 12,439 | New | +$23,000.00 | <0.0001 | |
| New York State Common Retirement Fund | $22,000.00 | 0.02 | 11,900 | 0% | +$0 | <0.0001 | |
| Toroso Investments Llc | $21,947.00 | 0.02 | 11,612 | New | +$21,947.00 | <0.0001 |